Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lupin Buys Shionogi Brands As Japan Market Opens To Indian Firms

Executive Summary

Kyowa, the Japanese arm of Indian major Lupin, is buying a basket of mature products including CNS drugs Rhythmy and Resmit from Shionogi. As innovator companies seek to shed older products in Japan, generic firms, especially Indian ones, are taking advantage to expand in the world's second largest pharmaceutical market.


Related Content

Astellas Offloads Japan Product Basket To Private Equity Group
Sun Taps Mitsubishi For Ex-Novartis Japan Portfolio
M&A Trends: The Growing Indian Appetite
Lupin's Metformin US Outlook Stays Sunny; Russian Buy Under Review
Deal Watch: Roche Aborts But Regeneron, Amgen and Pfizer Sign Up
ANALYSIS: Inside The Sun-Novartis Japan Deal
Sun Enters Japan Through Divested Novartis Portfolio
Takeda Enters Generics Space With Teva Tie-Up
Lupin Top Execs On Asia Push And Japan Generic Consolidation


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts